IJARP Impact Factor(2018): 4.908

International Journal of Advanced Research and Publications!

Cardiometabolic Risk Factors In Patients With Hyperparathyroidism

Volume 1 - Issue 2, August 2017 Edition
[Download Full Paper]

Author(s)
Said Azzoug, Fahima Bala, Djamila Meskine, Farida Chentli
Keywords
hyperparathyroidism, cardio metabolic risk factors, dysglycemia
Abstract
Hyperparathyroidism is one of the more common endocrine diseases and is often asymptomatic. But, even if it is asymptomatic, it may increases the cardio metabolic risk. Subjects and Methods: In this retrospective study we have looked for the presence of cardio metabolic risk factors in 84 patients (72F/12M) with a mean age of 51 years presenting with hyperparathyroidism. We have also looked for the predictive factors of the occurrence of dysglycemia by comparing patients with dysglycemia (G1) to those with normoglycemia (G2). Results: 31.3% of our patients were overweight whereas 28.8% were obese. 32.5% had high blood pressure (HBP), 31% had low HDL-cholesterol level, 41.8% had high triglyceride level and 28.5% had dysglycemia (19% had diabetes and 9.5% had prediabetes). G1 patients were older than those of G2: 58 ± 11 vs. 48.6 ± 15.3 years. Familial background of HBP was found in 45.8% (G1) vs. 27% (G2). The body mass index was of 27±5 kg/m2 (G1) vs. 26.5±5 kg/m2 (G2). Mean serum calcium level was 11.1±2 mg/dl (G1) vs. 10.7 ±2.2 mg/dl (G2). Mean PTH level was 236 ±222 pg/ml (G1) vs. 382±479 pg/ml (G2). Mean 25(OH) vitamin D level was 11±4 ng/ml (G1) vs. 12±8 ng/ml (G2). Conclusion: Cardio metabolic risk factors are frequent in patients with hyperparathyroidism. Compared to normoglycemic patients, patients with dysglycemia are older, but there were no differences in the other parameters analyzed in this study.
References
[1] A. García-Martín, R. Reyes-García, JM. García-Castro, M. Quesada-Charneco, F. Escobar-Jiménez, M. Muñoz-Torres. Cardiovascular risk factors in patients with asymptomatic primary hyperparathyroidism. Endocrinol Nutr. 2014 Aug 5. pii: S1575-0922(14)00168-5.
[2] R. Luboshitzky, Y. Chertok-Schaham, I. Lavi, A. Ishay. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest. 2009;32(4):317-21.
[3] MG. Cardenas, KJ. Vigil, GB. Talpos, MW. Lee, E. Peterson, DS. Rao. Prevalence of type 2 diabetes mellitus in patients with primary hyper parathyroidism. Endocr Pract. 2008;14(1):69-75.
[4] M. Procopio, G. Magro, F. Cesario, A. Piovesan, A. Pia, N. Molineri, G. Borretta. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyper parathyroidism. Diabet Med. 2002 ; 19(11):958-61.
[5] HN. Hulter, JC. Melby, JC. Peterson, CR. Cooke. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens. 1986; 2: 360-70.
[6] MF. McCarty, CA. Thomas. PTH Excess may promote weight gain by impeding catecholamine-induced lipolysis --- implications forthe impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses. 2003;61: 535-42.
[7] MJ. Bolland, AB. Grey, GD. Gamble, IR. Reid. Association between primary hyperparathyroidism and increased bodyweight: a meta-analysis. J Clin Endocrinol Metab. 2005;90:1525-30.
[8] D. Sukumar, NC. Partridge, X. Wang, SA. Shapses. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab 2011, 96: 1852-8.
[9] GC. Ogard, MD. Engelmann, C. Kistorp, SL. Nielsen, H. Vestergaard. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005, 63: 493-8.
[10] MH. Christensen, SN. Dankel,Y. Nordbø, JE. Varhaug, B. Almås, EA. Lien. Primary hyperparathyroidism influences the expres-sion of inflammatory and metabolic genes in adipose tissue.PLoS ONE. 2011;6:e20481.
[11] SK. Chakrabarti, D. Biswas, S. Chaudhury, R. Jain, M. Kataria, S. Ghosh. Diabetes due to recurrent pancreatitis secondary to hypercalcemia due to primary hyperparathyroidism. Indian J Endocrinol Metab. 2013;17(Suppl 1):S212-4.